Erman Akkus highlights new platinum derivatives Aurkine 16 and 18 for cancer treatment
Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X:
“New platinum derivatives ‘Aurkine 16 and 18’
Selectively target DNA in cancer cells
Both naïve and cisplatin-resistant CCA
Greater efficacy than cisplatin
No evident systemic toxicity
Potential to be a breakthrough, looking forward to clinical trials!”
Title: New platinum derivatives selectively cause double-strand DNA breaks and death in naïve and cisplatin-resistant cholangiocarcinomas
Journal: Journal of Hepatology
Authors: Irene Olaizola, Mikel Odriozola-Gimeno, Paula Olaizola, Francisco J. Caballero-Camino, Noelia Pastor-Toyos, Mireia Tena-Garitaonandia, Ainhoa Lapitz, Beatriz Val, Amanda R. Guimaraes, Maitane Asensio, Maider Huici-Izagirre, Colin Rae, David de Sancho, Xabier Lopez, Pedro M. Rodrigues, Elisa Herraez, Oscar Briz, Laura Izquierdo-Sanchez, Aitziber Eleta-Lopez, Alexander M. Bittner, Ana Martinez-Amesti, Teresa Miranda, Sumera I. Ilyas, Chiara Braconi, Maria J. Perugorria, Luis Bujanda, Iván Rivilla, Jose J.G. Marin, Fernando P. Cossio, Jesus M. Banales
More posts featuring Erman Akkus on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023